IDEXX Laboratories (NASDAQ:IDXX) had its price objective hoisted by analysts at Bank of America from $200.00 to $220.00 in a research note issued on Friday. The firm currently has a “buy” rating on the stock. Bank of America’s target price would suggest a potential upside of 18.05% from the company’s current price.
A number of other brokerages have also recently weighed in on IDXX. Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. BidaskClub cut shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Piper Jaffray Companies lifted their price objective on shares of IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a report on Thursday. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Finally, Canaccord Genuity restated a “buy” rating and issued a $210.00 price objective on shares of IDEXX Laboratories in a report on Monday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. IDEXX Laboratories currently has an average rating of “Buy” and an average price target of $189.71.
Shares of IDEXX Laboratories (NASDAQ IDXX) traded down $7.59 on Friday, hitting $186.36. 769,517 shares of the company’s stock were exchanged, compared to its average volume of 462,038. IDEXX Laboratories has a 1-year low of $125.02 and a 1-year high of $198.73. The firm has a market capitalization of $16,250.00, a PE ratio of 63.39, a PEG ratio of 2.08 and a beta of 0.58. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $148.35, for a total transaction of $2,670,300.00. Following the completion of the transaction, the chief executive officer now owns 1,064,573 shares in the company, valued at approximately $157,929,404.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Jonathan W. Ayers sold 54,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the transaction, the chairman now owns 1,064,573 shares of the company’s stock, valued at approximately $161,091,186.36. The disclosure for this sale can be found here. Insiders sold 112,160 shares of company stock valued at $17,252,185 in the last 90 days. Company insiders own 2.77% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Advisors Capital Management LLC acquired a new position in IDEXX Laboratories during the 3rd quarter worth approximately $262,000. Koch Industries Inc. grew its holdings in IDEXX Laboratories by 44,533.1% during the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after acquiring an additional 1,396,113 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of IDEXX Laboratories by 7.8% during the 3rd quarter. Wells Fargo & Company MN now owns 338,968 shares of the company’s stock worth $52,706,000 after buying an additional 24,510 shares during the last quarter. Cabot Wealth Management Inc. purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $1,359,000. Finally, Macquarie Group Ltd. lifted its position in shares of IDEXX Laboratories by 7.0% during the 3rd quarter. Macquarie Group Ltd. now owns 38,000 shares of the company’s stock worth $5,909,000 after buying an additional 2,500 shares during the last quarter. Institutional investors own 86.54% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
